Jan Cools

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Medicine, Genetics, Hematology +14

A Tyrosine Kinase Created by Fusion of the <i>PDGFRA</i> and <i>FIP1L1</i> Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

Jan Cools, Daniel J. DeAngelo, Jason Gotlib et al. · New England Journal of Medicine · 2003 · 1.7K citations · Full text

Life Sciences, Genetics, Hematology +15

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez et al. · Gastroenterology · 2005 · 494 citations · Full text

Medicine, Oncology, Pharmacology +15

Fusion of TEL, the ETS-Variant Gene 6 (ETV6), to the Receptor-Associated Kinase JAK2 as a Result of t(9; 12) in a Lymphoid and t(9; 15; 12) in a Myeloid Leukemia

Pieter J. Peeters, Sophie Raynaud, Jan Cools et al. · Blood · 1997 · 484 citations · Full text

Life Sciences, Genetics, Molecular Biology +11

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1–like phenotype

Hilde Brems, Magdalena Chmara, Mourad Sahbatou et al. · Nature Genetics · 2007 · 473 citations

Life Sciences, Genetics, Molecular Genetics +10